Mastercard: Another Triangle in Big TechSometimes people forget that the credit-card companies are members of the technology sector, but they are. We’ve already covered the bullish triangles in other tech names like Microsoft and Salesforce.com . And now Mastercard is showing a similar pattern.
MA has faced resistance around $282, which closely matches its 200-day simple moving average (SMA). Meanwhile it’s made steadily higher lows, forming an almost perfect ascending triangle.
The other interesting thing about MA is that it’s so clearly tied to consumer spending and the economy. That could make it a logical go-to stock for institutional investors as the coronavirus lockdowns end. It’s also a liquid options underlier, averaging more than 30,000 options contracts per session.
Looking at the weekly chart, we see MA has formed two inside weeks in a row. Combined with the April monthly high and the 200-day SMA, there’s a lot of importance in the $282-285 area. This creates the potential for buyers to get more active if it starts to break through this zone.
This is one to watch as the global economy reopens.
Technologystocks
IT'S TIME TO CONTINUE LONGING $UBERContextual immersion trading strategy idea.
Uber Technologies, Inc. develops and operates proprietary technology applications primarily in the United States, Canada, Latin America, Europe, the Middle East, Africa, and the Asia Pacific.
The share price rose after good earnings. I see some preconditions the share price will continue growing.
The demand for shares of the company still looks higher than the supply.
These and other conditions can cause a rise in the share price in the next days.
So I opened a long position from $32,62;
stop-loss — $30,41.
Information about take-profits will be later.
Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision.
Always do your own analysis before making deals. When you use any materials, do not rely on blind trust.
You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy.
If you like my content, you can subscribe to the news and receive my fresh ideas.
Thanks for being with me!
Alphabet Pulls Back to Post-Earnings LevelAlphabet has struggled more with coronavirus than some other big technology names because of its reliance on advertising. GOOGL is still below its old $1 trillion market cap level, even after Microsoft , Amazon.com and Apple reclaimed (or kept) that honor.
GOOGL had a decent earnings report on April 28. The growth in non-search businesses like YouTube was especially interesting. This remains the potential kicker for Sundar Pichai and the Internet giant: a huge, under-monetized division with the potential to start delivering. YouTube’s a secular driver. If you think the worst of the economic crisis is over, traditional search advertising could be a cyclical catalyst as well.
GOOGL gapped higher after that quarterly report, and earlier this week reached its highest price since February 25. It then pulled back with the rest of the market and is now holding the same $1,340 area where it traded immediately after earnings. It’s also near a post-breakout consolidation zone from December and the 100-day simple moving average (SMA).
Given its massive size, GOOGL is unlikely to rally without the rest of the market behind it. If you think S&P 500 will hold this area after touching a three-week low today, GOOGL may interest you around these levels.
Alibaba: False Breakdown as Earnings ApproachOne of the striking things about this earnings season has been the broad strength across technology and e-commerce. Whether you’re looking at Shopify , Twilio or PayPal , one company after another has rallied despite the coronavirus pandemic.
And now one of the biggest names of all, Alibaba, has some interesting patterns as its quarterly numbers approach.
Two things stand out on BABA’s chart. First is the $188-190 support zone. That area was first important back in November 2017, then again in March-April 2019.
The bears tried to take a stab at that same level last week, but were stopped dead in their tracks the next day.
This level is also meaningful as a confluence area with the rising 200-day simple moving average (SMA).
Speaking of moving averages, BABA had a false breakdown under its 50-day SMA a few sessions ago. Its rebound back above that level today could be another signal for the bears to back off.
The next earnings date hasn't been officially announced yet, but TradingView estimates it will be on May 11.
Sell SHOP - management must agree the valuation is crazy.By issuing shares at these prices, shortly after reporting a good quarter, management must either see tough times ahead, or are just being greedy. Either way, diluting shareholders opportunistically is not a good sign. Expect more equity dilution from other tech darlings.
NDX - Potential Gap Fill? - Time to be VERY careful nowMarkets are anything but boring, idiotic perhaps, but not boring that's for sure.
The Nasdaq is just shy of 7% from the prior ATH, despite the fact that the economy has still NOT reopened, many small businesses are in tatters, large business are hat in hand to the Fed and Treasury for bailouts AND north of 30 million Americans are unemployed.
Initial Claims:
So how do we play this market?
Carefully...very carefully...
The Nasdaq could very easily fall away from here, hitting it's head on the 78.6% fib retracement, mind you, this WOULD NOT invalidate the latest move higher, crazy as it may seem.
Should the Nasdaq fall away from here i would expect to see support show up at the 38.2% fib level, currently around the 8,200-8,400 mark, this would also coincide with a nice potential gap fill around the same area.
Nasdaq potential trajectory to the downside:
BUT, this is largely going to be dependent on how the 'cream' of the crop perform, namely the FAANG stocks (FB, AMZN, AAPL, NFLX, GOOGL).
Which recently have shrugged off any concerns about a potential global depression and have in fact make new ATHs.
FAANG stocks make new ATHs:
What to look for?
~Should we see TWO closes above the 78.6% fib retracement, then the odds are more skewed towards the bullish case for a gap fill at the 90 fib level or even a retest of prior highs.
~ If however we head lower, say two closes below the 9 ema, then i would begin to favor the bearish case to 8,200-8,400 more.
Lending credence to the bear case is the rather neutral/ bearish RSI reading at the moment is a good gauge of potential direction, which at press time is NOT confirming the latest moves higher.
In any case, I do firmly believe that the markets WILL head lower soon, BUT the fact that the 'obvious' path is down, leads me to believe that we may well be looking at one of the greatest bull trap in recent memory.
-TradingEdge
Salesforce.com: Another Software Name, Another Bullish TriangleSoftware has been one of the strongest industry groups lately as investors view it as largely immune to Covid-19. On Tuesday we highlighted Microsoft’s bullish triangle , and today another major player has a similar pattern.
Salesforce.com is pushing against the $165 area that held it in check last year (flagged in this idea ). CRM has also made a series of higher lows since getting slammed lower back on April 21. The 50-day simple moving average (SMA) was providing resistance at that time, but now the stock is fighting past that line in the sand.
CRM has also managed to get back above its 200-day SMA in the process.
Traders may want to use the April high of $165.30 as an entry trigger.
Bullish Ascending Triangle in MicrosoftMicrosoft has been squeezing into a range with breakout potential.
Of all the big technology companies, it may emerge as the biggest beneficiary of coronavirus thanks to its cloud-computing, business software and videogaming.
Last week’s earnings report beat across the board, but MSFT didn’t move much because it’s been trapped in a bullish ascending triangle. And now it may be trying to break out of that pattern.
The triangle started taking shape in the first half of April. It became more clear after April 17, when MSFT hit resistance around $179. That’s near the close on February 21, immediately before the coronavirus correction began.
Pfizer and BioNTech Dose First Participants in the U.S. Hey fellow Traders from TradingView, this is an update to the actual Situation and my previous Analysis
If you agree with my Analysis or find it useful , please leave me a like for my work it would be greatly appreciated.
Im still bullish and optimistic that BNTX participation will have a huge global impact. The stock seems to be news related, so expect it to make huge moves when they finally will announce to have completed those first worldwide clinical studies.
The Moving Averages are lining up and signalizing us there will soon be a Price expansion.
Assuming the 55 MA line serves as a support we cacn expect the stock to bounce off that and rise to the resistance battleground area.
I´d place my Stop Loss below the next support pivot at either 36.85 to not risk gettiong shaken out before the upcoming outbreak. If you can handle that amount of risk.
If not a LOD SL is always a great way to reduce risk.
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today that the first participants have been dosed in the U.S. in the Phase 1/2 clinical trial for the BNT162 vaccine program to prevent COVID-19. This U.S. trial is part of a global development program, and the dosing of the first cohort in Germany was completed last week.
"The Phase 1/2 study is designed to determine the safety, immunogenicity and optimal dose level of four mRNA vaccine candidates, and is to be evaluated in a single, continuous study. The dose level escalation portion (Stage 1) of the Phase 1/2 trial in the U.S. will enroll up to 360 healthy subjects into two age cohorts (18-55 and 65-85 years of age). The first subjects immunized in Stage 1 of the study will be healthy adults 18-55 years of age. Older adults will only be immunized with a given dose level of a vaccine candidate once testing of that candidate and dose level in younger adults has provided initial evidence of safety and immunogenicity. Sites currently dosing participants include NYU Grossman School of Medicine and the University of Maryland School of Medicine. The University of Rochester Medical Center/Rochester Regional Health and Cincinnati Children’s Hospital Medical Center will begin enrollment shortly."
Source by: NASDAQ:BNTX FWB:22UA investors.biontech.de
Remember, this is only my opinion after considering all facts and informing myself about the Up/Downside of this stock.
So no financial advise is given here. Always do your own reasearch.
Thank you for taking the time and i hope to see you again in my next post!
See you there
Sincerly,
Sebastian - TradingExperts Europe
Activision - to reach new highsFor those that have been following my analysis on ATVI, you'll take note of how he price passed through the highlighted zone and bounced out in the upwards direction in the area I marked a couple of weeks back. With earnings coming in tomorrow, given the fact that COVID-19 has kept people home and the kickoff of the Call of Duty World Championship, I expect an earnings beat as well as a rally this week into the $70-$75 range before another rest period.
NASDAQ100Short position on NSDQ. Chart on daily. I follow the Fibonacci retracements and have a look on MACD.
Targets:
1. 8566
2. 8202
3. 7837
4. 7366
5. 6658
MSFT is likely to go down for some time .NASDAQ:MSFT is likely to go down to around 172 before bouncing up from there .If it doesn't , If it continues dropping below the 172 area and closes considerably below the 172 in an upcoming day (With a bearish candle) then price is likely to continue its drop until around the 167.5 mark .For people who bought MSFT earlier (Long term investment) I think it would be wise to hold it as long as it doesn't considerably close below the 164,5$ mark.
Advanced Micro Devices: The Bears Are Trying, But…Advanced Micro Devices was the top-performing member of the S&P 500 in both 2018 and 2019. Its last earnings report on April 28 was very middle-of-the-road. Results beat, and then management tried to talk down demand. Other chips like Intel and Qualcomm have struck a similarly cautious tone.
However, investors know some positives lay in the future. They may see the bigger chip cycle (cloud, AI, 5G, mobile) resuming sooner rather than later, and not want to remain negative on a company that’s repeatedly shown leadership.
This sentiment may be evident on the chart because AMD has refused to make new lows after earnings.
The key level seems to be the April 21 close of $52.92. Remember that was a big negative session for the S&P 500, one day after oil went negative.
Buyers defended AMD during that volatile day. The stock actually had more volume on April 21 than yesterday, following quarterly results.
Let’s see if this price area continues to provide support. It also gives potential buyers a decent risk-management level in case the shares break to the downside.
Apple’s Range Is Tightening as Earnings ApproachApple's range is tightening with earnings due on Thursday afternoon. Is a breakout coming?
The iPhone maker has stayed above its 8-day exponential moving average since the market jumped back to life on April 6. There were a few tests below it, but now that line is squeezing up to the top of the recent range around $288.25. It’s also near the 100-day simple moving average (SMA).
A tight pattern like this, especially with waning volume, suggests traders may be waiting for quarterly results to jump in. Notice how the 5-day Average True Range (ATR) is back to its tightest reading since February 21, immediately before the coronavirus selloff began.
AAPL is also holding above its 50-day SMA. The stock had a false breakdown under that line on April 21, but it quickly rebounded and has stayed above it since.
From a fundamental perspective, Wall Street seems fully aware that coronavirus will hurt both supply and demand. IPhone production was delayed by factory outages. Big hits to income from the millions of lost jobs will also weigh on unit sales. But how long will those headwinds last?
Investors seem to be looking out a little further in time and seeing Tim Cook’s initiatives paying off: Cheaper phones draw more users into AAPL’s growing services business. That’s a positive for valuations because recurring revenues tend to command higher multiples than hardware sales.
AAPL has pursued that strategy lately by releasing the iPhone SE for $399. It also rolled out services like App Store and iCloud in 20 more countries across Africa, Europe and the Middle East.
In conclusion, AAPL has made several major transformations over the years: First from Macs to iPods. Then, from iPods to iPhones. Now it’s evolving from iPhones to services. The result is a stickier business model with more operating leverage. Covid-19 or no Covid-19, the progress seems on track.
Tesla Is Parked Above a Key Level. Will it Speed into Earnings?Tesla turned before the rest of the market, and quickly doubled from its low. Now the electric-car maker is parked above a key level, making traders wonder if it may accelerate higher.
TSLA bottomed on March 18 , four sessions before the S&P 500 capitulated. It also passed above its 50-day simple moving average (SMA) on April 14 and has remained there, even with the broader market struggling at that line.
It squeezed into a tight range as it consolidates and is now trying to break out of a small triangle. The stock will be in focus this week because earnings are due Wednesday afternoon.
While few companies have been immune to the impact of coronavirus on global economies, TSLA has actually had some positive news before its results. On April 2 the company said first-quarter vehicle deliveries would crush estimates (88,400 vs 79,900 forecast). Then on April 15, LMC Automotive estimated that registrations in the key Chinese market rose more than 400 percent between February and March.
Finally, some bigger perspective: TSLA’s market cap is $133 billion, but it still isn’t in the S&P 500 index. If it were, it would rank No. 41 between McDonald’s and Medtronic . The real story here could be that a major growth stock for the next several years may be sitting right in front of us, in the middle of its second major historic move. Earnings are nigh, short interest is high and a brief consolidation phase may be in the rearview mirror.
Bullish Technical Setup provided by ALEC / Through 26NASDAQ:ALEC
Hey Guys, today i´d like to showcase you a sharp ooking Long Setup for a shorter time frame.
We are looking here at an uplifting and trending Bio TECH Stock that has shows previous Strenght when the market had its weakness.
Alector, Inc. operates as a clinical-stage biopharmaceutical company. They are developing therapeutics for the treatment of neurodegenerative diseases including frontotemporal dementia (FTD), Alzheimer's disease, and Parkinson's disease.
No real profits are yet achieved for the Company but it still has a solid looking balance sheet.
ALEC had a appropriate Consolidation Phase last week where it bounced back multiply times from the 26$ Resistance Level.
Looking at the Hourly the Stock set ups very well it its given Range
The Moving Averages dispaly that the Stock should be ready for a breakout expansion with a confirmation from high Volume following through.
My Entry would be at 26.10 to not get trapped.
Targets are 30, 32 and 36
I´d set my SL at LOD and then trail it with a 15min candel upwards to not give back any gains.
This is only my opinion on technical Analysis and not a buy or sell recommendations. Do your own research before jumping into a bandwagon.
Please leav me a like or a comment if you want to see more of my Analysis !
It would mean a lot to me and id´be greatly appreciated.
Thanks,
Sebastian - TradingExperts EU
Biontech AG Outbreak - First COVID-19 human vaccine trial test Hey fellow Trader,
The uprising Biotechnology company from NASDAQ:BNTX Mainz, Germany is on its final steps from developing a vaccine for the actual Bio-weapon health crisis from the "new flu" .
With Rolf Zinkernagel a brilliant Scientiests that can proudly say to win a nobelprice and a strong financial background , from big names in the Pharmaceutical field.
When BioNTech AG announced to start with the first human vaccine tests after getting an approval in Europa , a US approval should follow shortly after also.
We should expect News from those test in end May/june and if they´ve managed to create a proven vaccine afterwards im staying LONG in this Outbreak because its Trending and the Chances are high for a good R/R.
A Golden Cross is forming and the Overall Stock is positive and with a low beta so less correlation risk in this given "Crazy Market" .
So with a break of the 56 level we should see a strong move up.
Goals are high and i think it could touch the 100 mark again with reactive move down to given support levels if they arent successful with their vaccine Therapy.
STOPLOSS tight at 49,45
I hope this was helpful but it only displays my opionion and no financial adivce is given here.
Sincerly,
Sebastian
Bullish with earnings released soonPrice made a double top, and never retested the neck line
Price is now respecting the demand zone
price also appears to be respecting the 50 fib level
while the stock market has been looking rough, tech stocks are doing fairly well
also to me, it appears that this stock kind of mirror microsoft ( i mean it would make sense if you ask me) and im really bullish on MSFT
CYBERARK SOFTWARE: The Underdog of the CybersecurityCyberArk is a smallcap security company offering Privileged Account Security ( e.g. financial services, energy, retail, healthcare).
Cause of the Covid19-Crash the Cybersecurity section crushed down to -33% but we are seeing fast recovery in the Cyber Sector recording to the First Trust NASDAQ Cybersecurity ETF (Blue Line).
I expect that Cyberark is going to have a big bound upwards. Your Christian S.
Battery technology stock poised to move out...Livent Corp. looks like it has completed the b wave of a ongoing Zigzag formation. If the pattern continues, the stock should move up towards the $6.50 range for a hefty nearly fifty percent move.
Zynga, Unfazed by Market Crash, May be Coiling for a BreakoutAt times like this, with the vast majority of stocks below their 200-day simple moving averages (SMA), a name like Zynga stands out.
The video-game developer has consolidated in a key price zone for the last 10 months. It gapped higher on a strong earnings report in early February and then slid along with the rest of the market as coronavirus spread.
But it barely pulled back. ZNGA only closed below its 200-day SMA a handful of times before clawing higher. It made its low on March 17, almost a week before the broader S&P 500. The longer-term chart also seems to be forming a cup-and-handle pattern.
ZNGA was already benefiting from stronger ad revenue before the coronavirus correction. Now it has the added catalyst of users spending more time on their mobile devices as they stay home. Analysts including Cowen and Bank of America have cited this trend in research notes. Oppenheimer also initiated the stock at “outperform” on March 18 with a $7.50 target price.
Traders may want to watch ZNGA around its current levels. The stock had a weekly high of $6.85 on March 10, which was resistance again last Friday. A breakout of this zone, combined with potential steadying in the market, may draw buyers. Given how long it’s consolidated, now could be the time for an upside extension off the 200-day SMA.